The FDA's recent classification of 19 peptides into Category 2 imposes stringent compounding conditions, reflecting heightened regulatory momentum under Sections 503A and 503B. While this move is intended to improve safety and manufacturing standards, persistent high costs and policy gaps threaten to push many patients back toward a gray market for essential therapies like tirzepatide and semaglutide. As stakeholders seek equitable access through expanded insurance coverage and standardized compounding protocols, patient optimism clashes with frustration over treatment discontinuations.
“Many peptides fall squarely into that Category 2 bucket.”
“The FDA has been actively reviewing peptide nominations, and in some cases, substances have been removed from Category 2.”
“The FDA recently reminded compounders... that strict conditions must be met to qualify for exemptions under Sections 503A and 503B.”
“In September 2023, the FDA moved 19 peptides into Category 2, effectively restricting their use in compounding.”
“The FDA emphasized that injectable peptides carry well-known risks, particularly immune reactions ranging from mild irritation to severe, life-threatening anaphylaxis.”
“Kennedy has presented reclassification as a harm-reduction strategy, placing peptides in environments where manufacturing standards are more transparent and impurities are better managed.”
“The FDA’s traditional framework requires evidence that drugs are both safe and effective before they can be used.”
“Peptides reveal the limitations of both approaches.”
Title not available for this citation.
“PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.”
Title not available for this citation.
“PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.”
Title not available for this citation.
“PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.”
Title not available for this citation.
“Tirzepatide (TZP-MJ), originally approved for type 2 diabetes (T2D), has demonstrated significant weight loss beyond glycemic improvement.”
